Works matching IS 25233548 AND DT 2023 AND VI 43 AND IP 9
Results: 11
Cover Image, Volume 43, Issue 9.
- Published in:
- Cancer Communications, 2023, v. 43, n. 9, p. i, doi. 10.1002/cac2.12483
- By:
- Publication type:
- Article
Uncovering the IL‐1β‐PCAF‐NNT axis: A new player in ferroptosis and tumor immune evasion.
- Published in:
- Cancer Communications, 2023, v. 43, n. 9, p. 1048, doi. 10.1002/cac2.12473
- By:
- Publication type:
- Article
Combined local therapy and CAR‐GPC3 T‐cell therapy in advanced hepatocellular carcinoma: a proof‐of‐concept treatment strategy.
- Published in:
- Cancer Communications, 2023, v. 43, n. 9, p. 1064, doi. 10.1002/cac2.12472
- By:
- Publication type:
- Article
Bifidobacterium adolescentis orchestrates CD143<sup>+</sup> cancer‐associated fibroblasts to suppress colorectal tumorigenesis by Wnt signaling‐regulated GAS1.
- Published in:
- Cancer Communications, 2023, v. 43, n. 9, p. 1027, doi. 10.1002/cac2.12469
- By:
- Publication type:
- Article
Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple‐negative breast cancer to immune checkpoint inhibitors.
- Published in:
- Cancer Communications, 2023, v. 43, n. 9, p. 1003, doi. 10.1002/cac2.12465
- By:
- Publication type:
- Article
HMMR alleviates endoplasmic reticulum stress by promoting autophagolysosomal activity during endoplasmic reticulum stress‐driven hepatocellular carcinoma progression.
- Published in:
- Cancer Communications, 2023, v. 43, n. 9, p. 981, doi. 10.1002/cac2.12464
- By:
- Publication type:
- Article
Clinical utility of circulating tumor DNA sequencing with a large panel in patients with advanced soft‐tissue sarcomas.
- Published in:
- Cancer Communications, 2023, v. 43, n. 9, p. 1051, doi. 10.1002/cac2.12461
- By:
- Publication type:
- Article
Worldwide trends in esophageal cancer survival, by sub‐site, morphology, and sex: an analysis of 696,974 adults diagnosed in 60 countries during 2000‐2014 (CONCORD‐3).
- Published in:
- Cancer Communications, 2023, v. 43, n. 9, p. 963, doi. 10.1002/cac2.12457
- By:
- Publication type:
- Article
A phase II study on Mefatinib as first‐line treatment of patients with advanced non‐small‐cell lung cancer harboring uncommon EGFR mutations.
- Published in:
- Cancer Communications, 2023, v. 43, n. 9, p. 1059, doi. 10.1002/cac2.12456
- By:
- Publication type:
- Article
Single‐cell transcriptomics provides insights into the origin and immune microenvironment of cervical precancerous lesions.
- Published in:
- Cancer Communications, 2023, v. 43, n. 9, p. 1055, doi. 10.1002/cac2.12451
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Cancer Communications, 2023, v. 43, n. 9, p. 961, doi. 10.1002/cac2.12306
- Publication type:
- Article